SCHEMBL8360588

SCHEMBL8360588

Cc1cc2ccccc2n1C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.51
PDGFRB P09619 9/20 0.51
TP53 P04637 3/20 0.45
KDM4E B2RXH2 2/20 0.45
SLC9A1 P19634 1/20 0.44
MCL1 Q07820 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
HSP90AA1 P07900 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31122079 1.00 KDR (0.51) KDRPDGFRBTP53KDM4ESLC9A1
Benzene SCHEMBL28136154 0.98 KDR (0.50) KDRPDGFRBTP53KDM4ESLC9A1
Hydrochloric Acid SCHEMBL28136871 0.98 KDR (0.50) KDRPDGFRBTP53KDM4ESLC9A1
SCHEMBL28136870 0.92 KDR (0.49) KDRPDGFRBTP53KDM4ETSHR
Maleic Acid SCHEMBL28136866 0.91 KDR (0.45) KDRPDGFRBTP53KDM4ESLC9A1
Fumaric Acid SCHEMBL28136873 0.91 KDR (0.45) KDRPDGFRBTP53KDM4ESLC9A1
Succinic Acid SCHEMBL28136152 0.91 OXER1 (0.47) KDRPDGFRBTP53KDM4EMEN1
Malic Acid SCHEMBL28136944 0.83 OXER1 (0.41) KDRPDGFRBTP53KDM4ETSHR
SCHEMBL28548039 0.83 POLB (0.52) TP53KDM4EMCL1TSHRMEN1
SCHEMBL5967722 0.83 MCL1 (0.49) TP53KDM4EMCL1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108367000-A THERAPEUTIC AGENT FOR BREAST CANCER 卫材R&D管理有限公司 2018-08-03 CN claimed
CN-105073730-B monocyclic pyridine derivatives 卫材R&D管理有限公司 2017-10-13 CN claimed
CN-107205996-A Therapeutic agent for bile duct cancer 国立癌症研究中心 2017-09-26 CN claimed
CN-106660997-A Salts of monocyclic pyridine derivatives and crystals thereof 卫材R&D管理有限公司 2017-05-10 CN claimed
CN-110878070-B Method for preparing asymmetric urea compound 中国科学院化学研究所 2021-08-31 CN disclosed
CN-110878070-A Method for preparing asymmetric urea compound 中国科学院化学研究所 2020-03-13 CN disclosed
CN-106660997-B Salts of monocyclic pyridine derivatives and crystals thereof 卫材R&D管理有限公司 2019-05-21 CN disclosed
CN-108367000-A THERAPEUTIC AGENT FOR BREAST CANCER 卫材R&D管理有限公司 2018-08-03 CN disclosed
CN-105073730-B monocyclic pyridine derivatives 卫材R&D管理有限公司 2017-10-13 CN disclosed
CN-107205996-A Therapeutic agent for bile duct cancer 国立癌症研究中心 2017-09-26 CN disclosed
CN-106660997-A Salts of monocyclic pyridine derivatives and crystals thereof 卫材R&D管理有限公司 2017-05-10 CN disclosed
EP-0810991-B1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1999-04-14 EP disclosed
EP-0810991-A1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS Novartis AG (CH) 1997-12-10 EP disclosed
WO-1996026183-A1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1996-08-29 WO disclosed